罕见病研究2024,Vol.3Issue(2) :246-251.DOI:10.12376/j.issn.2097-0501.2024.02.015

视神经脊髓炎谱系疾病的疾病修饰治疗进展

Advances in Disease-Modifying Therapy of Neuromyelitis Optic Spectrum Disorders

张玄龄 陈超阳 魏然 周颖
罕见病研究2024,Vol.3Issue(2) :246-251.DOI:10.12376/j.issn.2097-0501.2024.02.015

视神经脊髓炎谱系疾病的疾病修饰治疗进展

Advances in Disease-Modifying Therapy of Neuromyelitis Optic Spectrum Disorders

张玄龄 1陈超阳 1魏然 1周颖2
扫码查看

作者信息

  • 1. 北京大学第一医院药剂科,北京 100034
  • 2. 北京大学第一医院药剂科,北京 100034;北京大学第一医院药物临床试验机构,北京 100034
  • 折叠

摘要

视神经脊髓炎谱系疾病(NMOSD)是一种严重的炎症性脱髓鞘疾病,其治疗主要包括急性期治疗和缓解期预防发作治疗.NMOSD缓解期的疾病修饰治疗(DMT)可有效减少疾病复发,延缓残疾程度的进展.目前国内外常用于DMT的药物包括经典免疫抑制、B细胞表面抗原单克隆抗体、补体靶向单克隆抗体、白细胞介素-6受体靶向单克隆抗体等,本文就NMOSD的DMT药物有效性、安全性及在中国上市情况进行综述.

Abstract

Neuromyelitis optic spectrum disorders(NMOSD)is a serious inflammatory demyelinating disease.Clinical treatment of NMOSD mainly involves acute phase treatment and remission phase prevention treatment.Disease-modifying therapy(DMT)in remission phase of NMOSD can effectively reduce disease re-currence and delay disability progression.At present,the drugs commonly used for DMT at home and abroad in-clude classical immunosuppression,B-cell surface antigen monoclonal antibody,complement targeting mono-clonal antibody,IL-6 receptor-targeting monoclonal antibody,etc.This paper mainly reviews the DMT drugs ef-ficacy,safety,as well as the marketing status of NMOSD.

关键词

视神经脊髓炎谱系疾病/疾病修饰治疗/药物治疗

Key words

neuromyelitis optic spectrum disorders/disease-modifying therapy/medication

引用本文复制引用

基金项目

"重大新药创制"科技重大专项(2017ZX09201008-008)

"重大新药创制"科技重大专项(2017ZX09304029-006-001)

出版年

2024
罕见病研究

罕见病研究

CSTPCD
ISSN:
参考文献量38
段落导航相关论文